BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9807	Companies
196721	Keywords
127727	Articles
104587	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 01/19/2026 at 09:10, 17 days 1 hour ago

BioNxt Announces Promising Results in Cladribine Study

Multiple Sclerosis Cladribine BioNxt Solutions Pharmacokinetics Sublingual ODF
PRESS RELEASE

published on 01/19/2026 at 09:05, 17 days 2 hours ago

BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
BioNxt Solutions reports successful comparative pharmacokinetics study in pigs for sublingual cladribine ODF formulation, showing superior bioavailability and potential benefits for Multiple Sclerosis therapy. Internal analysis ongoing

Multiple Sclerosis Drug Delivery BioNxt Solutions Cladribine ODF Comparative Pharmacokinetics
BRIEF

published on 12/17/2025 at 09:10, 1 month 19 days ago

BioNxt Advances with Rapid-Dissolving Drug Technology

Autoimmune Diseases Drug Delivery Patent Protection Thin-film Technology Dysphagia
BRIEF

published on 12/17/2025 at 09:10, 1 month 19 days ago

BioNxt fait des progrès dans le domaine des médicaments à dissolution rapide

Maladies Auto-immunes Administration De Médicaments Technologie Des Couches Minces Protection Par Brevet Dysphagie
PRESS RELEASE

published on 12/17/2025 at 09:05, 1 month 19 days ago

Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
BioNxt Solutions Inc. announces breakthrough in drug delivery for dysphagia, securing first national-level patent for thin-film platform, targeting autoimmune markets with bioequivalent cladribine treatment

BioNxt Solutions Inc. Drug Delivery Dysphagia Thin-film Platform Autoimmune Markets
BRIEF

published on 12/09/2025 at 09:10, 1 month 27 days ago

BioNxt Develops "Melt in Your Mouth" Cladribine for MS Patients

Multiple Sclerosis Cladribine BioNxt Solutions Melt In Your Mouth Drug-delivery
BRIEF

published on 12/09/2025 at 09:10, 1 month 27 days ago

BioNxt développe une cladribine « fondante » pour les patients atteints de SEP.

Sclérose En Plaques Cladribine Solutions BioNxt Administration De Médicaments Fond Dans La Bouche
PRESS RELEASE

published on 12/09/2025 at 09:05, 1 month 27 days ago

BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
BioNxt Solutions Inc. is developing a sublingual cladribine ODF to enhance MS treatment access. The innovative technology aims to improve swallowing difficulties and increase therapy adherence

BioNxt Solutions Inc. Multiple Sclerosis Drug Delivery Cladribine ODF Melt In Your Mouth
BRIEF

published on 12/01/2025 at 09:10, 2 months 4 days ago

BioNxt Solutions to Acquire IP for Sublingual Chemotherapy Drug

Intellectual Property Chemotherapy BioNxt Solutions Sublingual Drug Immunosuppressant Market
BRIEF

published on 12/01/2025 at 09:10, 2 months 4 days ago

BioNxt Solutions va acquérir la propriété intellectuelle d'un médicament de chimiothérapie sublinguale

Propriété Intellectuelle Chimiothérapie Solutions BioNxt Médicament Sublingual Marché Des Immunosuppresseurs

Accesswire

Published on 02/05/2026 at 09:05, 2 hours ago

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Published on 02/05/2026 at 01:35, 9 hours 30 minutes ago

Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 11 hours 5 minutes ago

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 12 hours 40 minutes ago

55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 18:00, 17 hours 5 minutes ago

Lithium South AGSM Update

View all ACCESSWIRE

EQS Group

Published on 02/05/2026 at 10:48, 16 minutes ago

EQS-Adhoc: Evonik Industries AG: Executive Board adjusts dividend policy
Published on 02/05/2026 at 10:05, 1 hour ago

VT Markets Powers Reliable Gold Trading Amid Extreme Market Volatility
Published on 02/05/2026 at 10:05, 1 hour ago

Signing of strategic technology supply and offtake agreement with Carester, US$20 million equity investment from the Industrial Development Corporation, and commencement of DFS for the Zandkopsdrift magnet rare earths and battery grade manganese
Published on 02/05/2026 at 09:00, 2 hours 4 minutes ago

Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY
Published on 02/05/2026 at 09:00, 2 hours 4 minutes ago

Original-Research: Limes Schlosskliniken AG (von NuWays AG): BUY

Les Echos

Published on 02/04/2026 at 18:04, 17 hours 1 minute ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 17 hours 1 minute ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 17 hours 20 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 17 hours 20 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 17 hours 20 minutes ago

Janvier 2026

View all LES ECHOS COMFI WIRE